Deirdre Jill Cohen MD

PubMed

• COMMIT: A Randomized Study of mFOLFOX6/Bevacizumab/Atezolizumab or Atezolizumab Alone as First-Line Treatment of Deficient DNA Mismatch Repair Metastatic Colorectal Ca...
  Caio Max Sao Pedro Rocha Lima, Greg Yothers, Thomas J George, Howard S Hochster, Hanna K Sanoff
  Journal of Clinical Oncology. 2026-07-29
• ECOG-ACRIN E6293: Phase II Study of Raltitrexed in Advanced Colorectal Cancer.
  Chengwei Peng, Paul Catalano, John Zalcberg, Ann D Thor, Louis M Weiner
  The Oncologist. 2026-04-10
• 3 citations
  Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer.
  Frank A Sinicrope, Fang-Shu Ou, Dirk Arnold, Walter R Peters, Robert J Behrens
  The New England Journal of Medicine. 2026-03-26

Journal Articles

• Targeting the Hedgehog Pathway: Role in Cancer and Clinical Implications of its Inhibition  
  Cohen DJ, Hematology/Oncology Clinics of North America, 6/1/2012
• Postoperative intraperitoneal 5-fluoro-2’-deoxyuridine added to chemoradiation in patients curatively resected (R0) for locally advanced gastric and gastroesophageal j...  
  Cohen DJ, Newman E, Iqbal S, Chang RY, Potmesil M, Ryan T, Donahue B, Chandra A, Liu M, Utate M, Hiotis S, Pachter HL, Hochster H, Muggia F, Annals of Surgical Oncology, 2/1/2012
• Phase I dose-escalating study of biweekly fixed-dose rate gemcitabine plus pemetrexed in patients with advanced solid tumors  
  Yuan Y, Cohen DJ, Love E, Yaw M, Levinson B, Nicol SJ, Hochster HS, Cancer Chemotherapy and Pharmacology, 8/1/2011

Books/Book Chapters

• New Treatment Strategies for Metastatic Colorectal Cancer 
  Chapter: Second-Line Treatment of Metastatic Colorectal Cancer: Chemotherapy with Integration of Biologic Agents- Review of Current Data. 
  Page 47 - 68Cohen DJ and Hochster HSEditors: Edward Chu.New Haven, CT2008

Abstracts/Posters

• A phase 2, randomized trial of GVAX pancreas and CRS-207 immunotherapy versus GVAX alone in patients with metastatic pancreatic adenocarcinoma: Updated results.
  Le DT, Wang-Gillam A, Picozzi, Jr V, Greten TF, Crocenzi TS, Springett GM, Morse M, Zeh H, Cohen DJ, Fine RL, Onners B, Uram JN, Laheru D, Murphy A, Skoble J, Lemmens ..., J Clin Oncol, 1/1/2014
• Vismodegib (V), a hedgehog (HH) pathway inhibitor, combined with FOLFOX for first-line therapy of patients (pts) with advanced gastric and gastroesophageal junction (G...
  Cohen DJ, Christos PJ, Kindler HL, Catenacci DV, Bekaii-Saab T, Tahiri S, Janjigian YY, Gibson MK, Chan E, Rajdev L, Urba S, Wade JL, Kozuch P, Love E, Vandris K, Take..., J Clin Oncol, 1/1/2013
• The MEK inhibitor selumetinib ([SEL], AZD6244, ARRY-142886) plus irinotecan (IRI) as second-line therapy for KRAS-mutated (KRASm) metastatic colorectal cancer (CRC).
  Hochster HS, Messersmith WA, O'Neil BH, Groshen SG, Lenz H, Cohen DJ, Denlinger CS, Gold PJ, Eckhardt SG, Locker GY, Ames P, McKinley M, Leichman L, Academic GI Cancer..., J Clin Oncol, 1/1/2013

Lectures

• Phase II multi-institutional study of nivolumab (Nivo), cabiralizumab (Cabira), and stereotactic body radiotherapy (SBRT) for locally advanced unresectable pancreatic ... 
  2019 ASCO Annual Meeting - 6/1/2019
• A phase I/II study of GSK3145095 alone and in combination with anticancer agents including pembrolizumab in adults with selected solid tumors. 
  2019 ASCO Annual Meeting - 6/1/2019
• “Multidisciplinary Management of Localized Gastroesophageal Junction Cancers” 
  1/16/2014